• Kalantar A, Rezaei M, Jafarzadeh Kohneloo A, Taghizadeh-Ghehi M. A nationwide study on consumption of opioid analgesics in Iran from 2000 to 2018. International Journal of Clinical Pharmacy. 2023. 45:397–405

 

  • Heidari Sh, Kargar M. Low Dose Antipsychotics for the Treatment of Delirium in Hospitalized Elderly Patients and Their Effects on QTc Interval. Journal of Pharmacy Practice.2023. doi:10.1177/08971900221108966

 

  • Ekhtiari Kolour SR, Shahrami B, Kargar M, Taghvaye Masoumi Hr, Amini Sh, Vaezi M, Hadjibabaie M, Mohammadi M, Sadeghi K. Adherence to practice guidelines for the management of febrile neutropenia in patients undergoing hematopoietic stem cell transplantation: An observational study in a referral center in Iran. Journal of Oncology Pharmacy Practice.2023. 29(5):1112-1118

 

 

  • Sharifan A, Bahreini M, Najmeddin F. Blood Pressure Control Following Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: Insights from a Triple-Blind, Randomized, Clinical Trial. Journal Of Clinical Pharmacology.2023. doi:10.1002/jcph.2294

 

  • Tazerouni H, Labbani-Motlagh Z, Sadeghi K. Population pharmacokinetics of vancomycin in patients with diabetic foot infection: a comparison of five models. Journal of Diabetes & Metabolic Disorders. 2023. doi:10.1007/s40200-023-01259-5

 

 

  • Tort S, Sharifan A. For premenopausal women, does calcium with or without vitamin D increase bone mineral density (BMD)? Cochrane Clinical Answers.2023. doi:10.1002/cca.4233

 

  • Tort S, Sharifan A. Do oral class I and III antiarrhythmic drugs help maintain sinus rhythm after catheter ablation of atrial fibrillation?
  •  Cochrane Clinical Answers.2023. doi:10.1002/cca.4275

 

  • Paydar P, Ebrahimpour S, Zehtab Hashemi H, Mohamadi M, Namazi S. Design, Development and Evaluation of an Application based on Clinical Decision Support Systems (CDSS) for Over-The-Counter (OTC) Therapy: An Educational Interventions in Community Pharmacists. Journal of Advances in Medical Education & Professionalism. 2023. 11(2):95-104

 

 

  • Ansari R, Ghaderkhani S, Namazi S. Trimethoprim/sulfamethoxazole desensitization in an HIV-positive patient with previous Stevens-Johnson syndrome; a failed study. Daru-Journal of Pharmaceutical Sciences. 2023. 31(1): 69-73

 

  • Sharifan A, Ciapponi A. How do cephalosporins compare with other antimicrobials for people with enteric fever? Cochrane Clinical Answers.2023. https://doi.org/10.1002/cca.4225

 

  •   Sharifan A, Ciapponi A. What are the benefits and harms of hyperimmune immunoglobulin (hIVIG) from human plasma for treating adults with moderate/severe COVID-19? Cochrane Clinical Answers.2023. doi.10.1002/cca.4146 

 

  • Sharifan A, Ciapponi A. Does hormonal contraception increase the risk of thromboembolism in women with COVID-19? Cochrane Clinical Answers.2023. doi.10.1002/cca.4212

 

  • Sharifan A, Ciapponi A. For people with hereditary angioedema (HAE), how do different drugs compare with placebo for HAE attack prevention? Cochrane Clinical Answers.2023. doi.10.1002/cca.4202

 

  • Sharifan A, Ciapponi A. What are the effects of antifibrinolytic (AF) therapy for people with aneurysmal subarachnoid hemorrhage (SAH)? Cochrane Clinical Answers.2023. doi.10.1002/cca.4166

 

  • Taghizadeh-Ghehi M, Emami M, Heidari K. A recent clinical trial on efficacy of citalopram to prevent stroke recurrence: unresolved controversies. Journal of Clinical Neuroscience.2023. doi.10.1016/j.jocn.2023.02.010

 

 

  • Ciapponi A, Sharifan A. For adults with cancer receiving anthracyclines, does dexrazoxane prevent cardiotoxicity? Cochrane Clinical Answers.2022. doi:10.1002/cca.4126

 

  • Ciapponi A, Sharifan A. For children with cancer receiving doxorubicin, does dexrazoxane help prevent cardiotoxicity? Cochrane Clinical Answers.2022. doi:10.1002/cca.4125

 

  •  Ciapponi A, Sharifan A. What are the benefits and risks of non-replicant viral vector vaccines for preventing COVID-19? Cochrane Clinical Answers.2022. doi:10.1002/cca.4076

 

  •  Ciapponi A, Sharifan A. What are the benefits and risks of RNA-based vaccines for preventing COVID-19? Cochrane Clinical Answers.2022. doi:10.1002/cca.4073

 

  •  Ciapponi A, Sharifan A. What are the benefits and risks of protein subunit vaccines for preventing COVID-19? Cochrane Clinical Answers.2022. doi:10.1002/cca.4077

 

  •  Ciapponi A, Sharifan A. What are the benefits and risks of inactivated virus vaccines for preventing COVID-19? Cochrane Clinical Answers.2022. doi:10.1002/cca.4074

 

  •  Ciapponi A, Sharifan A. What is the accuracy of combinations of menopausal status, ultrasound scan(USS), and biomarkers for the diagnosis of ovarian cancer (OC) in pre and postmenopausal women with symptoms suspicious of OC? Cochrane Clinical Answers.2022. doi:10.1002/cca.4105

 

  •  Ciapponi A, Sharifan A. Do pharmacological interventions prevent weight gain among people with schizophrenia? Cochrane Clinical Answers.2022. doi:10.1002/cca.4130

 

  •  Ciapponi A, Sharifan A. How do different interventions for adults with basal cell carcinoma (BCC) compare with surgical excision (SE)? Cochrane Clinical Answers.2022. doi:10.1002/cca.4144

 

 

 

  •  Ciapponi A, Sharifan A. How does the use of lowdose computed tomography (LDCT) for lung cancer screening affect outcomes? Cochrane Clinical Answers.2022. doi:10.1002/cca.4111

 

  •  Ciapponi A, Sharifan A. What are the effects of antiplatelet agents for people in the chronic phase of deep venous thrombosis (DVT)? Cochrane Clinical Answers.2022. doi:10.1002/cca.4070

 

  •  Ciapponi A, Sharifan A. What are the effects of antiplatelet agents for people in the acute phase of deep venous thrombosis (DVT)? Cochrane Clinical Answers.2022. doi:10.1002/cca.4069

 

 

 

 

 

  •  Sharifan  A, Ciapponi A. How does intravenous or oral iron compare with no treatment for people with cancer and anemia? Cochrane Clinical Answers.2022. doi:10.1002/cca.4059

 

  •  Tort S, Sharifan  A. How do different therapies compare with placebo and with each other in people with pancreatic neuroendocrine tumors(pNETs)? Cochrane Clinical Answers.2022. doi:10.1002/cca.4032

 

  •  Tort S, Sharifan  A. How do different therapies compare with placebo and with each other in people with gastrointestinal neuroendocrine tumors (gNETs)? Cochrane Clinical Answers.2022. doi:10.1002/cca.4042

 

 

 

 

 

 

  • Tort S, Sharifan  A. How does a computerized physician order entry (CPOE)/clinical decision support systems (CDSS) compare with control/paperbased system to reduce medication errors? Cochrane Clinical Answers.2022. doi:10.1002/cca.4019

 

  •  Ciapponi A, Sharifan  A. What are the effects of chemotherapy, in addition to radiotherapy and/or surgery, for adults with oral cavity cancer, oropharyngeal cancer, or both? Cochrane Clinical Answers.2022. doi:10.1002/cca.4000

 

  •  Tort S, Sharifan  A. In adults admitted to hospital, does medication reconciliation help reduce medication errors? Cochrane Clinical Answers.2022. doi:10.1002/cca.4018

 

  •  Ciapponi A, Sharifan  A. How does weekly compare with triweekly paclitaxel with carboplatin for first line treatment of women with epithelial ovarian cancer? Cochrane Clinical Answers.2022. doi:10.1002/cca.3981

 

  •  Ciapponi A, Sharifan  A. What are the benefits and harms of perioperative enhanced recovery ayer surgery(ERAS) for women with suspected or confirmed gynecological cancers? Cochrane Clinical Answers. 2022. doi:10.1002/cca.3984

 

  •  Tort S, Sharifan  A. What are the effects of poly (ADPribose) polymerase (PARP) inhibitors as maintenance therapy for women with advanced epithelial ovarian cancer (EOC)? Cochrane Clinical Answers. 2022. doi:10.1002/cca.3996

 

  • Tort S, Sharifan  A. What are the effects of poly (ADPribose) polymerase (PARP) inhibitors for women with newly diagnosed epithelial ovarian cancer (EOC) during chemotherapy? Cochrane Clinical Answers.2022. doi:10.1002/cca.3965

 

 

 

  • Sharifan  A. How does lamotrigine compare with lithium for maintenance treatment of bipolar disorder? Cochrane Clinical Answers.2022. doi:10.1002/cca.3979

 

  •  Sharifan  A. In adults with overweight and obesity without type 2 diabetes mellitus, how does a lowcarbohydrate diets compare with a balancedcarbohydrate diet for reducing weight and cardiovascular risk? Cochrane Clinical Answers.2022. doi:10.1002/cca.3968

 

  •  Sharifan  A. In adults with overweight and obesity and type 2 diabetes mellitus, how does a lowcarbohydrate diet compare with a balancedcarbohydrate diet for reducing weight and cardiovascular risk? Cochrane Clinical Answers.2022. doi:10.1002/cca.3970

 

  •  Burch G, Sharifan  A. For women with metastatic breast cancer, how do capecitabinecontaining and noncapecitabinecontaining regimens compare? Cochrane Clinical Answers.2022.doi:10.1002/cca.3754

 

  •  Burch G, Sharifan  A. For men with hormonesensitive prostate cancer, how does degarelix compare with a gonadotropinreleasing hormone (GnRH) agonist?Cochrane Clinical Answers.2022.doi:10.1002/cca.3866

 

  •  Burch G, Sharifan  A. For women with localized/invasive breast cancer, how do neoadjuvant capecitabine‐ containing and noncapecitabinecontaining regimens compare?Cochrane Clinical Answers.2022. doi:10.1002/cca.3755

 

  •   Burch G, Sharifan  A. For women with invasive breast cancer, how do adjuvant capecitabinecontaining and noncapecitabinecontaining regimens compare?Cochrane Clinical Answers.2022. doi:10.1002/cca.3753